MRZ-9547
chemical compound
MRZ-9547, also known as (R)-phenylpiracetam, (R)-phenotropil, or (R)-fonturacetam, is a selective dopamine reuptake inhibitor (IC50Tooltip half-maximal inhibitory concentration = 14.5 μM) that was developed by Merz Pharma. It is the (R)-enantiomer of the racetam and nootropic phenylpiracetam (phenotropil; fonturacetam).
The drug was under development for the treatment of fatigue associated with Parkinson's disease and was in phase 1 clinical trials for this indication in June 2014. However, no recent development has been reported as of November 2017. There was also interest in MRZ-9547 for treatment of fatigue in people with depression and other conditions, but this was not pursued.
Similarly to other dopamine reuptake inhibitors and related agents, MRZ-9547 has been found to have pro-motivational effects in animals and to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine.
The drug, as the enantiopure (R)-enantiomer of phenylpiracetam, was first described in the scientific literature by 2014.
“MRZ-9547” enters the record as chemical compound. Crown Archives preserves that source wording while asking what MRZ-9547, chemical and compound can confirm, complicate or overturn.
Why this record matters
“MRZ-9547” is worth following because a concise public description often conceals a longer documentary argument. Here, MRZ-9547, chemical and compound provides the most credible route into that argument.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Mar 4, 2026. The linked authority identifier is Q128934138. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2014 and 2017.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “MRZ-9547”, its source revision and the description used here.
- Expand the search: follow MRZ-9547 primary sources, MRZ-9547 archive and MRZ-9547 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “MRZ-9547”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “MRZ-9547” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.